Vaxart, Inc.
NASDAQ:VXRTBiotechnology
-$0.01 today
- Market cap
- $129.30M
- Beta
- 1.09
- P/E (TTM)
- 3.6
- EPS (TTM)
- $0.15
Volume 0.12M
Average 0.41M
Returns on capital
Vaxart, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
18.6%
avg -80.3%
ROIC
17.2%
avg -104.0%
ROA
8.8%
avg -66.3%
Analysis
ROE is currently the strongest return metric at 18.6% versus its period average of -80.3%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Steven Lo | President, Chief Executive Officer & Director | USD 1.07M | 59 | 2.49M | 1.03% |
James F. Cummings | Chief Medical Officer | USD 744.27K | 60 | 924.18K | 0.38% |
Sean N. Tucker | Senior Vice President & Chief Scientific Officer | USD 657.02K | 58 | — | — |
Laurie Hastings | Senior Vice President of Human Resources | — | — | — | — |
Shaily Jaini Garg | Senior Vice President of Clinical Development & Project Management | — | — | — | — |
Rajesh Kapoor | Senior Vice President of Quality | — | — | — | — |
Edward Berg | Senior Vice President & General Counsel | — | 62 | — | — |
Jeroen Grasman | Chief Financial Officer, Principal Accounting Officer & Principal Financial Officer | — | 56 | — | — |
Compensation is shown in the reported currency; data updated Jun 18, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Mar 28, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$6,530.00
Sells
0
$0.00
Net Transaction Value
+$6,530.00
Net buying
Most Active
Watson W. Mark
1 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| May 22, 26May 22, 2026 | Watson W. Mark Direct | Buy | $6.5K$6,530.00 |
Summary
Insiders reported 1 buys worth $6,530.00 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $6,530.00. Watson W. Mark was the most active insider with 1 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +1204.0% | -10.6% (4yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +1204.0% over three years. Forward estimates point to Revenue at -10.6% (4yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Vaxart, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about VXRT's management, answered from reported figures.
Who manages VXRT?
Vaxart, Inc. (VXRT) lists 8 active executives. The top listed executive is Sean N. Tucker, Senior Vice President & Chief Scientific Officer.
Are VXRT insiders buying or selling?
Recent insider activity shows net buying of $18.13M.
Continue the stock analysis
Jump to another research area for this company.